Seres Therapeutics (MCRB) EBIT Margin (2016 - 2026)

Seres Therapeutics (MCRB) posted EBIT Margin of 5839.94% for Q1 2026, down 32.01% sequentially from 4423.97% in Q4 2025.

Seres Therapeutics (MCRB) EBIT Margin (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported EBIT Margin for 10 years, with the latest figure at 5839.94% in Q1 2026.

Quarterly EBIT Margin changed N/A year-over-year to 5839.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7640.98% (changed N/A YoY) and the FY2025 annual result came in at 11910.14%, changed N/A from the prior year.
EBIT Margin fell to 5839.94% in Q1 2026 per MCRB's latest filing, from 4423.97% in the prior quarter.
Over five years, EBIT Margin peaked at 39.16% in Q2 2023 and troughed at 14382.58% in Q3 2023.
A 4-year average of 5030.55% and a median of 4423.97% in 2025 frame the typical range for EBIT Margin.
The widest YoY moves for EBIT Margin: up 524681 bps in 2023, down 1266635 bps in 2023.
Over 4 years, EBIT Margin stood at 177.54% in 2022, then surged by 117 bps to 29.32% in 2023, then tumbled by 15187 bps to 4423.97% in 2025, then slumped by 32 bps to 5839.94% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 5839.94%, 4423.97%, and 6403.7% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn	30.15%
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn	32.54%
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn	-35.57%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.30 Bn	26.46 Bn	-	19.75%
10	Seres Therapeutics	44.36 Mn	44.36 Mn	-	-2,890.35%

Download Data